Yandong Shen, PhD

CLL research fellow
Royal North Shore Hospital, New South Wales, Australia

n/a

Presentation(s):

• (1553093) Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon

  Friday, October 6, 2023
  1:30 PM – 1:40 PM EDT